Crucial Innovations Corp. (OTC: CINV), Announces Completion of Reverse Merger with Eco Equity, Medical Cannabis operator in Zimbabwe, Africa
October 26, 2022 16:06 ET
|
CRUCIAL INNOVATIONS CORP.
Las Vegas, Nevada, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Crucial Innovations Corp (OTC: CINV), a Nevada Company today announced that has completed its previously announced reverse merger by acquiring...
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron)
December 02, 2021 04:30 ET
|
Helsinn Healthcare S.A.
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global...
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea
July 31, 2018 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV is one of the most common and distressing side effects of cancer chemotherapyIncluded as a treatment option...
TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
October 25, 2017 19:15 ET
|
TESARO, Inc.
VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
April 26, 2017 08:30 ET
|
TESARO, Inc.
VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...
TESARO Receives Positive CHMP Opinion for VARUBY®
February 27, 2017 02:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...
TESARO Announces Five Abstracts to be Presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2016 17:30 ET
|
TESARO, Inc.
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016...
TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
March 23, 2016 09:00 ET
|
TESARO, Inc.
WALTHAM, Mass., March 23, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for...
TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
March 14, 2016 08:05 ET
|
TESARO, Inc.
WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA)...
Midatech Agrees to Acquire Marketed Oncology Product, Zuplenz®, From Galena Biopharma, Inc.
December 18, 2015 02:00 ET
|
Midatech Pharma PLC
OXFORDSHIRE, United Kingdom, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM:MTPH), the international specialty pharmaceutical company focused on developing and commercialising products in...